STA-5326 mesylate

DRUG2 trials

Sponsors

Synta Pharmaceuticals Corp.

Conditions

Crohn's Disease

Phase 2

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

CompletedNCT00138840

Synta Pharmaceuticals Corp.Crohn's Disease

Start: 2005-08-31Target: 282Updated: 2008-12-04

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

CompletedNCT00234741

Synta Pharmaceuticals Corp.Crohn's Disease

Start: 2005-11-30Target: 12Updated: 2008-12-04